A retrospective real-world major bleeding (MB) comparison of direct oral anticoagulants (DOAC) and low molecular weight heparin (LMWH) in genitourinary cancer-associated venous thromboembolism (GU-CAVTE) with reported randomized clinical trials (RTC).

Authors

null

Ulyana Dashkevych

The University of Arizona Cancer Center, Tucson, AZ

Ulyana Dashkevych , Eric Brucks , Kathylynn Saboda , Juan Chipollini , Hani M. Babiker , Ali McBride , Alejandro Recio Boiles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 410)

DOI

10.1200/JCO.2021.39.6_suppl.410

Abstract #

410

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2021 ASCO Quality Care Symposium

Evaluation of direct oral anticoagulant use for cancer-associated venous thromboembolism (VTE) in lung cancer.

Evaluation of direct oral anticoagulant use for cancer-associated venous thromboembolism (VTE) in lung cancer.

First Author: Leila Rostamnjad

First Author: Alejandro Recio Boiles

Poster

2023 ASCO Annual Meeting

Apixaban versus rivaroxaban for treatment of acute deep venous thrombosis in patients with cancer.

Apixaban versus rivaroxaban for treatment of acute deep venous thrombosis in patients with cancer.

First Author: Brittany Miles